Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives
Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives
Moderna Inc. (NASDAQ:MRNA) stock plunged on Monday after the company announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses.
Moderna公司(納斯達克:MRNA)的股票在週一暴跌,此前該公司宣佈了業務更新和管道進展。Moderna表示,在2025年開始時,將重點關注一個優先的產品組合,針對呼吸道病毒、罕見疾病、腫瘤學以及潛伏和其他病毒。
The company will present at the 43rd Annual J.P. Morgan Healthcare Conference.
該公司將在第43屆年度摩根大通醫療健康會議上發言。
In September, Moderna unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products.
在九月份,Moderna在其年度研發日上公佈了關鍵更新,通過到2027年將年度研發支出減少11億美元,專注於十個優先產品。
The company expects R&D expenses to fall from $4.8 billion in 2024E to $3.6 billion—$3.8 billion in 2027.
公司預計研發費用將從2024年的48億美元下降到2027年的36億至38億美元。
Also Read: Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
另請閱讀:儘管對生物-疫苗安全性和衛生與公共服務部提名的政治擔憂,Moderna依然充滿信心。
The strategy, expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years.
該策略將產品組合擴展到腫瘤學和罕見疾病,使Moderna在未來三年內實現十個產品的批准。
In fiscal year 2024, Moderna achieved preliminary product sales of approximately $3 billion-3.1 billion, comprising $1.7 billion in the U.S. and $1.3 to 1.4 billion in the rest of the World.
在2024財年,Moderna實現了大約30億至-31億的初步產品銷售,其中在美國銷售爲17億,其餘世界銷售爲13億到14億。
This includes more than $3 billion in Spikevax sales and minimal sales from mRESVIA, its RSV Vaccine. Cash, cash equivalents, and investments at year-end 2024 were approximately $9.5 billion.
這包括超過30億的Spikevax銷售和來自其RSV生物-疫苗mRESVIA的微小銷售。到2024年年末,現金、現金等價物和投資約爲95億。
Moderna is accelerating and expanding its previous cost efficiency and prioritization programs and now projects cash cost reductions of $1.0 billion in 2025.
Moderna正在加速並擴大之前的成本效率和優先項目,現在預計2025年現金成本削減10億美元。
The company expects an additional $0.5 billion in potential cash cost savings in 2026. In September, the company announced its plans to reduce annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products.
該公司預計在2026年將額外節省5億美元的潛在現金成本。9月,該公司宣佈計劃到2027年減少11億美元的年度研發支出,從而專注於十個優先產品。
Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025 compared to the consensus of $2.95 billion, mostly in the second half of the year, primarily due to Spikevax and mRESVIA vaccine sales. Earlier, Moderna projected revenues of $2.5 to $3.5 billion by 2025.
Moderna現在預計2025年的營業收入爲15億到25億,相較於市場普遍預期的29.5億,主要是在下半年,這主要歸功於Spikevax和mRESVIA生物-疫苗的銷售。早些時候,Moderna預計到2025年的收入爲2.5億到35億。
The company expects to end 2025 with approximately $6.0 billion in cash and investments.
該公司預計到2025年將擁有約60億美元的現金和投資。
Moderna reported third-quarter revenue of $1.83 billion, compared with $1.83 billion a year earlier, beating the consensus of $1.25 billion.
Moderna報告第三季度營業收入爲18.3億,去年同期也爲18.3億,超過市場普遍預期的12.5億。
The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.
該公司將增長歸因於美國市場銷售的增加,這得益於更新版COVID-19生物-疫苗的提前推出。
Price Action: At last check on Monday, MRNA stock was down 19.20% to $34.13.
價格動態:最後一次檢查在週一,MRNA股票下跌19.20%,至34.13美元。
- Wayfair Expands Google Cloud Partnership To Tap AI For Cost Cuts And Efficiency
- Wayfair擴大與Google Cloud的合作,利用人工智能削減成本和提高效率。
Photo by Wolfilser via Shutterstock
圖片由Wolfilser提供,來源於Shutterstock
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因